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Objectives: Treatment outcome of MDR-TB is critically dependent on the proper use of second-line drugs as per
the result of in vitro drug susceptibility testing (DST). We aimed to establish a standardized DST procedure based
on quantitative determination of drug resistance and compared the results with those of genotypes associated
with drug resistance.
Methods: The protocol, based on MGIT 960 and the TB eXiST software, was evaluated in nine European reference
laboratories. Resistance detection at a screening drug concentration was followed by determination of resistance
levels and estimation of the resistance proportion. Mutations in 14 gene regions were investigated using estab-
lished techniques.
Results: A total of 139 Mycobacterium tuberculosis isolates from patients with MDR-TB and resistance beyond
MDR-TB were tested for 13 antituberculous drugs: isoniazid, rifampicin, rifabutin, ethambutol, pyrazinamide,
streptomycin, para-aminosalicylic acid, ethionamide, amikacin, capreomycin, ofloxacin, moxifloxacin and linezo-
lid. Concordance between phenotypic and genotypic resistance was .80%, except for ethambutol. Time to
results was short (median 10 days). High-level resistance, which precludes the therapeutic use of an antituber-
culous drug, was observed in 49% of the isolates. The finding of a low or intermediate resistance level in 16% and
35% of the isolates, respectively, may help in designing an efficient personalized regimen for the treatment of
MDR-TB patients.
Conclusions: The automated DST procedure permits accurate and rapid quantitative resistance profiling of first-
and second-line antituberculous drugs. Prospective validation is warranted to determine the impact on
patient care.
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Introduction
MDR-TB is a major problem in the global fight against TB.1–3 MDR-TB
is defined as resistance to at least isoniazid and rifampicin, the two
cornerstones of the standard short-course chemotherapy.4,5
Consequently, treatment of MDR-TB requires the use of second-line
drugs such as fluoroquinolones and aminoglycosides.6–8 Moreover,
the treatment of XDR-TB, i.e. MDR-TB with additional resistance to
fluoroquinolones and to amikacin, capreomycin or kanamycin,
requires a hand-tailored regimen using the few remaining
active drugs.
The treatment regimen for MDR- and XDR-TB is designed
according to the results of drug susceptibility testing (DST),
to ensure that the patient receives at least four drugs to which
the Mycobacterium tuberculosis strain is susceptible.6 – 8 Since
administration of appropriate therapy is a major prognostic factor,
accurate testing of second-line drugs is mandatory.6,7,9 – 12
However, this testing is generally poorly standardized and often
not quality controlled, which increases the risk of providing inad-
equate treatment.13–16
Several techniques, based on critical proportion and
critical concentration, have been described for M. tuberculosis
DST.8,9,17 – 19 Procedures for determining isoniazid and rifampicin
resistance are standardized and quality controlled, allowing for
relatively accurate determination of resistance rates for MDR-TB
surveillance at national and supranational levels.2,3,14,15,20,21
However, for second-line drugs these procedures are in part unre-
liable.13,15,22 In addition to poor reproducibility and extended
laboratory turnaround times, currently established techniques
provide no information on quantitative levels of drug resistance,
limiting the possibility of individualized treatment.
Commercially available molecular tests have been recently
implemented to detect mutations associated with resistance,
especially to isoniazid and rifampicin.23 In addition, reference
laboratories use more extended sequencing of molecular targets
to trace mutations associated with resistance.24,25
Mycobacterial growth indicator tube (MGIT) DST is a well-
established, standardized, semi-automated liquid system that pro-
vides reproducible results for first-line antituberculous drugs on the
basis of critical concentration testing using the Becton-Dickinson
(BD) MGIT 960 instrumentation (BD, Sparks, MD, USA).26 The suit-
ability of the system for second-line DST has also been evaluated.27
The TB eXiST (extended individual susceptibility testing) software
(BD) for interpretation of DSTon the basis of the MGIT instrumenta-
tion was developed to allow for continuous growth monitoring and
more detailed analysis.28 Here, we used the MGIT 960 instrumen-
tation equipped with the TB eXiST software to establish quantitative
DST for M. tuberculosis. The procedure was designed to combine the
endpoints of proportion and concentration testing with continuous
monitoring of bacterial growth. We validated the specificity of the
resistance detected by assessing the concordance with genetic
profiles of resistance. Quantitative DSTprovides results on quantita-
tive measures of resistance, which can help in optimizing treatment
regimens for MDR-TB patients.
Materials and methods
TB eXiST susceptibility testing protocol
The following antituberculous agents were tested: isoniazid, ethionamide,
rifampicin, rifabutin, ethambutol, streptomycin, para-aminosalicylic
acid, pyrazinamide, ofloxacin, moxifloxacin, amikacin, capreomycin and
linezolid. Antituberculous drugs were purchased from Sigma (St Louis,
MO, USA), except for pyrazinamide, linezolid and moxifloxacin, which
were provided by BD, Pfizer (Singapore) and Merck (Whitehouse Station,
NJ, USA), respectively. The drug concentrations selected for testing
(Table 1) were based on literature data on drug resistance, distribution
of the WT isolates [epidemiological cut-off (ECOFF)], critical concentrations
and in vivo drug concentrations.29 – 31 Stock solutions were prepared
in-house according to the manufacturers’ recommendations. A 10× solu-
tion was prepared in a volume of 200 mL and added to a 7 mL MGIT tube
along with 0.8 mL of OADC (BD). The 100% inoculum for MGIT testing was
prepared as follows. Briefly, strains were grown for an additional 2 days
after MGIT reached positivity (growth units.400) and used as pure inocu-
lum or strains were grown until 5 days after positivity and diluted to 1:5 in
7H9 supplemented with 10% OADC. After 10- and 100-fold dilutions in
MGIT medium, 0.5 mL of the 100%, 10% and 1% inocula were distributed
into the growth control tubes. The 1% inoculum was termed the growth
control (GC). An equal volume of 0.5 mL of the 100% inoculum was distrib-
uted in all the drug-containing tubes.
Strains were submitted to a screening protocol in order to distinguish
WT strains from strains suspected of resistance. This protocol consisted of
testing all drugs at the lowest drug concentration (Table 1) used as a
screening concentration, which corresponds to an optimized critical or
ECOFF concentration. Strains were submitted to a quantitative testing
protocol for those drugs for which they were suspected to be resistant
on the basis of screening concentration testing. For quantitative testing,
three to four concentrations per drug were used, except for pyrazinamide
where only one concentration was tested (Table 1).
MDR-TB cases and participating centres
Patients living in a European country at the time of diagnosis, whatever
their country of birth, were included if their M. tuberculosis strain was
MDR. Each centre included between 10 and 30 randomly chosen MDR
cases diagnosed in 2009; however, if there were ,10 cases, cases from
2010 were also included (Table S1, available as Supplementary data at
JAC Online). Clinical M. tuberculosis strains were subjected to resistome
analysis, i.e. a search for resistance-associated gene mutations by using
commercial line probe assays followed by PCR sequencing when neces-
sary. The gene regions studied are listed in Table 2.
Expert laboratories from nine European countries (Belgium, France,
Germany, Italy, the Netherlands, Portugal, Spain, Sweden and
Switzerland) participated in the study. This protocol received agreement
from the institutional ethics review boards of each centre. At least one rep-
resentative of each centre participated at the meetings organized: (i) at
the beginning of the study to agree on the protocol; (ii) following the cali-
bration and proficiency testing to optimize the protocol; and (iii) several
times during the study, i.e. when phenotypic (culture-based) and geno-
typic (gene mutation-based) results became available. Each centre fol-
lowed its established procedures for quality assurance. A steering
committee (E. C., M. V. and E. C. B.) met several times between the
group meetings and analysed the data. The interlaboratory reproducibility
of the protocol was assessed by comparing results obtained in each of the
participant laboratories for a set of 10 M. tuberculosis control strains: 5
strains for calibration (strain susceptibility was known to the participant)
and 5 strains for evaluating the proficiency testing (strain susceptibility
was unknown to the participant). These strains were provided by the
National Center for Mycobacteria, Institute of Medical Microbiology,
University of Zurich. In addition, each centre tested three to five WT pan-
susceptible clinical strains isolated in their country. The calibration panel
included three strains monoresistant to isoniazid (two with a katG S315T
mutation and one with an inhA c215t mutation conferring resistance also
to ethionamide), one strain resistant to isoniazid (katG S315T) and strep-
tomycin (rrs a523g), and one strain resistant to rifampicin and rifabutin
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(rpoB H526Y). The proficiency testing included two strains with resistance
to isoniazid (one inhA c215t and one katG S315T), one strain resistant
to rifampicin and rifabutin (rpoB S531L), one strain resistant to isoniazid
(katG S315T) and to streptomycin (rpsL K43R), and one strain resistant
to isoniazid (katG S315T) and to ethambutol (embB M306V).
Results
General features of TB eXiST DST
Drug resistance was initially detected by testing growth at the
screening drug concentration. Resistance was subsequently
quantified using higher drug concentrations. Since TB eXiST results
are available in real time, the growth was recorded in parallel in
control tubes and in drug-containing tubes. Figure 1 shows exam-
ples of growth curves for the three control tubes that contained
100%, 10% and 1% of the inoculum, resulting in three parallel
curves separated by a theoretical mean of 3.5 days, which is the
approximate time for an M. tuberculosis bacterial population to
multiply by 10-fold. When growth was observed in the drug-
containing tube before the GC (1% inoculum) was positive, this
indicated that .1% of the population was growing in the pres-
ence of the drug, i.e. as per proportion testing the strain is consid-
ered resistant at the corresponding drug concentration. By
studying bacterial growth at several drug concentrations, we
observed that the quantitative levels of resistance differed signifi-
cantly for the different antituberculous drugs and strains studied
(Figure 1).
The time to result, calculated as the time elapsed until the GC
became positive, was ,30 days in all centres. Statistics, calcu-
lated in three of the nine centres, showed mean and median
values of time to results between 10 and 11 days with a range
of 8–30 days. For most isolates, the time to positivity in the drug-
containing tubes was shorter than that of the GC and equal to that
of the 100% inoculum, since for most strains and drugs the resist-
ant proportion was close to 100%. The mean and median time to
obtain resistance testing results was calculated as 4 and 5 days
(range 3.5–13.5 days). Since growth curves were observed in a
real-time manner, resistance could be suspected as rapidly as
5 days after inoculation (Figure 1b and c).
All laboratories performed the calibration and proficiency test-
ing. A high rate of concordance (88%–97% with regard to strain
and drug) was observed. Adjustments were necessary for the
preparation of the stock solutions and we compared the results
of quantitative resistance with regard to strains with the same
genotype. This led to the exclusion of some of the data, for
which we suspected a problem of drug preparation: rifabutin (19
results were excluded), para-aminosalicylic acid (15 results were
excluded) and ethionamide (15 results were excluded).
Assessment of resistance for clinical strains
Testing growth at the screening concentration, i.e. the lowest drug
concentration, distinguished susceptible strains from resistant
strains (Table 1). Among the 139 MDR strains studied, resistance
to fluoroquinolones and to amikacin or capreomycin was
observed for 10 strains, corresponding to an XDR rate of 7.2%.
Resistant strains were submitted to quantitative testing for con-
firmation of resistance by retesting at the screening drug concen-
tration and for quantitative determination of the level of
resistance by studying growth at two to three additional higher
drug concentrations, except for pyrazinamide for which we tested
only a single concentration. The resistance patterns are presented
in Table 1.
All strains studied were MDR strains; however, various levels of
resistance were observed for isoniazid and rifampicin. For isoni-
azid, four levels of resistance were observed: low-level resistance
with growth at 0.1 mg/L, but no growth at 1 mg/L (11 strains); two
intermediate levels of resistance with growth at 0.1 and 1 mg/L,
but no growth at 3 and 10 mg/L (51 strains) or growth at 0.1, 1
and 3 mg/L, but no growth at 10 mg/L (58 strains); and high-level
resistance with growth at all drug concentrations (19 strains). For
rifampicin, the resistance was high level for 84% of the strains.
Cross-resistance to rifabutin was observed for 98% of the strains,
although the levels of resistance were different for the two
rifamycins.
In total, 720 resistant characters were observed, with a resist-
ant character being defined as one drug resistance observed in
one isolate. Low-level resistance, i.e. resistance to the screening
concentration, but susceptibility at higher drug concentrations,
was observed in 16% of the test results and at varying rates
according to the drug, from 5% (rifampicin) to 73% (ethambutol).
Conversely, high-level resistance, i.e. resistance to the highest
drug concentration tested, was observed in 49% of the isolates,
at rates between 2% (ethambutol) and 84% (rifampicin) accord-
ing to the drug. Antituberculous drugs could be divided into three
groups: predominantly high levels of resistance were observed for
rifampicin, rifabutin, amikacin; low levels of resistance were
mainly observed for ethambutol; and various levels of resistance
were observed for isoniazid, streptomycin, capreomycin, para-
aminosalicylic acid, ethionamide, ofloxacin and moxifloxacin.
Genotypic investigation of resistance
Data on the number of resistant strains in which we found at least
one mutation involved in resistance are presented in Table 2.
When molecular assays did not detect a mutation in a resistant
strain, we repeated the molecular analysis on bacteria grown in
the drug-containing tubes in order to avoid false test results
due to heteroresistance, i.e. coexistence of susceptible and resist-
ant bacteria.32,33 Genetic analysis was not done for para-
aminosalicylic acid resistance since the underlying genetic
mechanisms are still a matter of debate34 and not for linezolid
for which no resistant strains were observed. Overall, we observed
resistance mutations in .80% of the resistant strains, except for
ethambutol. Since the same mutation can confer cross-
resistance, we also compared the phenotypes of isoniazid and
ethionamide resistance in the case of inhA mutations, rifampicin
and rifabutin resistance in the case of rpoB mutations, amikacin
and capreomycin resistance in the case of a mutation in the rrs
1400 region and ofloxacin and moxifloxacin resistance in the
case of gyrA mutations.
katG mutations were the most prevalent mutation (85%) in
strains resistant to isoniazid, with S315T being the most frequent
katG mutation (96%) and associated with an intermediate level of
resistance (for the frequency of genotypes see Table 2, for geno-
type–phenotype relationships see Table 3 and for mutations in
strains with low-level resistance see Table 4). Mutations in the
inhA promoter region were associated with low-level isoniazid
resistance. rpoB mutations at position 531 were the most
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prevalent rifampicin resistance mutation (98/139, 71%) and were
associated with high-level resistance to rifampicin and rifabutin.
Altogether, 21 patterns of rpoB mutations were observed at 13
different codons, reflecting the diversity of the MDR strains in
the nine European countries. We confirmed that rpoB mutations
occurred also frequently at position 516 (12 strains) and at pos-
ition 526 (14 strains). Mutations at position 526 were mostly
associated with high-level resistance to rifampicin and rifabutin
(11/14 for rifampicin and 9/11 for rifabutin). In contrast, muta-
tions at position 516 were mostly associated with low-level resist-
ance to rifabutin (8/10 resistant strains) or even no resistance
(1/11 strains tested). Some, but not all, mutations are shown in
Table 3. Resistance to ethionamide was associated with muta-
tions in inhA (55%), in ethA (61%) or both (16%). Mutations in
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Figure 1. Representative results for quantitative resistance testing using the TB eXiST software. Growth in control tubes appears as blue lines; dotted line for
1:1; discontinuous line for 1:10 and continuous line for 1:100 (GC). (a) Low-level resistance to isoniazid (inhA c215t): resistance to isoniazid at 0.1 mg/L
(orange line) observed for 100% of the inoculum, but susceptibility at 1 mg/L (pink line). (b) Intermediate resistance to isoniazid (katG S315T): resistance to
isoniazid observed at 1 mg/L (pink line) and at 3 mg/L (green line) for 100% of the inoculum, but susceptibility at 10 mg/L (dark blue line). (c) Homogeneous
high-level resistance to ofloxacin (mutation gyrA D94A): resistance observed at 1 mg/L (pink line), 2 mg/L (green line) and 10 mg/L (dark blue line). (d)
Heteroresistance for ofloxacin and intermediate level of resistance (gyrA A90V): resistance observed at 1 mg/L (pink line) and 2 mg/L (green line) for
between 10% and 1% of the inoculum. See the text for interpretation of positive and negative growth results. INH, isoniazid; OFX, ofloxacin.
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ethA were various with deletions and stop codons introduced at
different sites of the gene sequence.
Phenotypic resistance to pyrazinamide, i.e. growth at the con-
centration of 100 mg/L, was highly associated with mutations in
pncA: various missense mutations for 53 strains, deletion muta-
tions for 4 strains and insertion mutations for 7 strains. In add-
ition, pyrazinamidase production was negative in 31/33 (94%)
resistant strains subjected to this biochemical test. This shows
that both altered pncA gene and absence of pyrazinamidase pro-
duction confirmed the resistant character. embB mutations at the
hot-spot 306 codon were observed in 70% of the resistant strains,
indicating either that the remaining strains harbour an unknown
mechanism of resistance or that the screening concentration
does not reliably discriminate between susceptible and resistant
strains. However, most of the strains devoid of embB mutations
showed only a low level of resistance. We noticed that mutations
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Figure 1. Continued
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M306V and M306I were not associated with the same level of
resistance to ethambutol: 42% (10/24) of the strains harbouring
the mutation M306V were resistant at 12.5 mg/L, but only 7%
(1/14) of those with the mutation M306I.
Resistance to streptomycin was associated either with a muta-
tion in the rrs 530 region or in the rpsL gene encoding the S12 ribo-
somal protein (position 43 or 88, numbering system of Escherichia
coli). For 23 streptomycin-resistant strains without rrs or rpsL
mutations, we found a gidB mutation in 16 strains. This was
more often associated with low-level resistance. For amikacin
resistance, we observed the mutation a1408g in the rrs gene in
all but four resistant strains, the latter showing resistance at a
low level only. Capreomycin resistance was observed as cross-
resistance with amikacin mediated by the rrs a1408g mutation
and also as isolated capreomycin resistance with mutation in
tlyA in five strains with no rrs mutation.
Resistance to fluoroquinolones correlated with gyrA mutations.
However, the correlation was stronger for moxifloxacin than for
ofloxacin, since three strains without gyrA and gyrB mutations
showed a low level of resistance to ofloxacin, but susceptibility
to moxifloxacin. The main problem for fluoroquinolone molecular
resistance detection was heteroresistance, since in 72% (18/25)
the gyrA mutation was evidenced only when molecular retesting
was done on bacteria grown in drug-containing medium.
Discussion
The lack of standardization and reproducibility in DST of M. tuber-
culosis hinders the control of TB disease and facilitates the spread
of drug-resistant organisms. This is especially true for second-line
agents. In this multicentre study, we evaluated the feasibility and
reliability of a standardized and automated DST procedure able to
quantify levels of drug resistance to first- and second-line antitu-
berculous drugs. The results of our DST measurements were vali-
dated by assessing the concordance with resistance-associated
gene mutations.
The primary objective of DST is to distinguish resistant strains
from susceptible strains, since resistance is prognostic of treat-
ment failure and relapse.35 Historically, two principles were
followed in DST: critical drug concentration and critical propor-
tion.13,36,37 Several DST methods, including newly developed
ones such as microscopic observation drug susceptibility, nitrate
reductase assay and colorimetric tests, have since been
described, all based on, but also limited by the principles of, critical
proportion and critical drug concentration.17,18,38 Unfortunately,
DST is done differently not only in different parts of the world,
but even within Europe. In Europe alone, three methods are
mainly used for DST of M. tuberculosis: proportion testing, the
absolute concentration method and the resistance ratio. As a
result of the different methods used, it is difficult to compare
the results from one laboratory with those from another labora-
tory, even for the same patient and the same strain. In addition,
for most drugs and techniques, only a single drug concentration is
tested while the quantitative levels of resistance may be import-
ant for treatment.
We aimed to improve DST for MDR M. tuberculosis by increasing
the accuracy of resistance detection as well as that of susceptibil-
ity assessment. Since exhaustive testing is required for MDR-TB
cases, we invested into a DST technique compatible with automa-
tion, standardization and rapid time to result. Automated proce-
dures offer significant advantages in terms of personnel handling,
standardization and quality control.
The DST procedure we developed follows a first step in which
bacterial growth is assessed in the presence of a ‘screening drug
Table 1. Phenotypic resistance observed for the 139 MDR strains of M. tuberculosis and detailed for the level of resistance (except pyrazinamide) by
quantitative DST
Drug (list of concentrations tested in mg/L) No. of resistant strainsa Low-level resistanceb Intermediate-level resistancec High-level resistanced
Isoniazid (0.1, 1, 3, 10) 139 11 (8%) 109 (78%) 19 (14%)
Rifampicin (1, 4, 20) 139 7 (5%) 15 (11%) 117 (84%)
Rifabutin (0.1, 0.4, 2) 118 11 (9%) 23 (19%) 84 (71%)
Ethambutol (5, 12.5, 50) 56 41 (73%) 14 (25%) 1 (2%)
PAS (4, 16, 64) 11 4 (36%) 3 (27%) 4 (36%)
Pyrazinamide (100) 65 NT NT NT
Streptomycin (1, 4, 20) 107 17 (16%) 22 (21%) 68 (64%)
Ethionamide (5, 10, 25) 57 10 (18%) 10 (18%) 37 (65%)
Amikacin (1, 4, 20) 22 4 (18%) 0 18 (82%)
Capreomycin (2.5, 5, 25) 24 4 (17%) 20 (83%) 0
Ofloxacin (1, 2, 10) 25 3 (12%) 19 (76%) 3 (12%)
Moxifloxacin (0.25, 0.5, 2.5, 7.5) 22 3 (14%) 18 (82%) 1 (5%)
Linezolid (1, 4, 16) 0 0 0 0
Total resistant characters 720 115 (16%) 253 (35%) 352 (49%)
PAS, para-aminosalicylic acid; NT, not tested.
aPhenotypic resistance was determined by growth at the screening concentration (in bold). This concentration was repeated in the quantitative DST
along with higher concentrations of the drug.
bLow-level resistance was defined as resistance at the screening concentration, but susceptibility at the intermediate drug concentration.
cIntermediate-level resistance was defined as resistance at the screening concentration and the intermediate concentration, but susceptibility at the
highest concentration.
dHigh-level resistance was defined as resistance at all concentrations tested.
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concentration’ that is close to the ECOFF described recently for iso-
niazid, rifampicin, ethambutol and fluoroquinolones.29 – 31 This
concentration is the smallest MIC value for the WT strains, i.e. sus-
ceptible strains will not grow at this concentration. The second
step was limited to strains resistant at the screening drug concen-
tration. This second step confirmed the resistance by retesting the
screening concentration and in addition provided a quantitative
assessment of resistance by testing different drug concentrations.
Knowing the level of resistance has two advantages: it gives infor-
mation on the putative mechanism of resistance and it may have
a significant clinical impact. Recent studies showed that an
increase in the dosage of isoniazid or rifampicin may improve
MDR outcome.39,40 A low level of resistance can also be overcome
by the use of a more potent drug such as the use of moxifloxacin
instead of ofloxacin in case of defined gyrA mutations.41,42 We
also confirmed that some strains resistant to rifampicin are only
low-level resistant to rifabutin and harboured a specific rpoB
mutation at codon 516.43,44 Although the clinical efficacy of rifa-
butin in these cases remains to be demonstrated, the lack of
effective drugs in some MDR cases may benefit from rifabutin if
still active. A low level of resistance to ethionamide, as we
observed in the majority of strains, may allow the use of an ethio-
namide booster in the future.45,46
In addition to quantitative DST determination, we also searched
for resistance-associated mutations with the view to confirm that
most of the strains categorized as resistant were not WT strains
and to increase our knowledge on the resistance levels these muta-
tions confer. Hot-spot mutations were found as expected in rpoB at
codon 531 for strains resistant to rifampicin, in katG at codon 315 for
strains resistant to isoniazid, in gyrA at codon 90 or 94 for strains
Table 2. Phenotypic and genotypic resistance per antituberculous drug among the 139 MDR strains of M. tuberculosis tested
Drug
Phenotypic resistancea Genotypic resistance
Gene and codon screened
(no. of strains with mutationb; %c)
no. of
resistant strains
resistance
rate (%)
no. of strains with
at least one mutation
rate of phenotypically resistant
strains with mutation (%)
Rifampicin 139 100 139 100 rpoB codons 511–533d (139; 100)
Rifabutin 118 100 118 100 rpoB codons 511–533d (118; 100)
Isoniazid 139 100 135 97 katG codon 315e and others (115; 85)
inhA promoter (30; 22)
inhA genef (15; 11)
Ethionamide 57 46 49 86 ethA (30; 61)
inhA promoter and inhA genef,g (27; 55)
ethR (0; 0)
Ethambutol 56 40 39 70 embB codon 306e (39; 100)
Pyrazinamide 65 47 64 98 pncA (64; 100%)
Streptomycin 107 77 98 92 rpsL codons 43–88d (68; 69)
rrs region 530d (17; 17)
gidBh (16; 16)
Amikacin 22 16 18 82 rrs region 1400d–1495 (18; 100)
Capreomycin 24 17 23 96 rrs region 1400d–1495 (18; 78)
tlyA i (5; 22)
Ofloxacin 25 18 22 88 gyrA codons 88e–94 (22; 100)
gyrBj (0; 0)
Moxifloxacin 22 16 22 100 gyrA codons 88e–94 (22; 100)
gyrBj (0; 0)
PAS 11 9 NA NA NA
Linezolid 0 0 0 0 NA
PAS, para-aminosalicylic acid; NA, not applicable (for PAS resistance, gene mutations have not been established; for linezolid, no resistant strains were
observed).
aPhenotypic resistance at the screening concentration.
bStrains may have mutations in several genes (see the text for details).
cPercentage of strains with mutation at this codon or in this gene.
dNumbering system of E. coli.
eNumbering system of M. tuberculosis.
fSequence of the structural inhA gene.
gSixty-seven out of 139 were studied for the entire inhA gene sequence.
hgidB was sequenced for 18 of the 23 streptomycin-resistant strains without mutation in both rrs and rpsL.
itlyA was sequenced for the six capreomycin-resistant strains without mutation in rrs.
jgyrB was sequenced in eight ofloxacin-resistant strains among which three strains were without mutation in gyrA.
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resistant to ofloxacin and moxifloxacin, in rpsL at codons 43 and 88
for strains resistant to streptomycin and in rrs at nucleotide a1408
for strains resistant to amikacin. Resistance mutations were scat-
tered in genes coding for ethA and pncA as described previously,
since many different mutations can confer a loss or decrease in
the function of these proteins, which activate ethionamide and pyr-
azinamide, respectively.47,48 Although some of the latter mutations
have not been described yet, we consider it unlikely that they are
related to simple gene polymorphisms.
To date, evidence is accumulating that the term ‘resistance’ in
M. tuberculosis is not a biological entity, but quite heterogeneous
and composed of quantitatively different levels of drug resistance.
Most significantly, the quantitatively different resistance levels—
low, moderate and high levels of resistance—are associated
with different genetic mutations.31,49 This biological diversity of
resistance is not recognized by the current critical concentration
or ECOFF testing, but requires measures of quantitative resistance
determination. Through this multicentre study, we established
and evaluated a standardized protocol for quantitative DST. The
procedure developed integrates the established principles of crit-
ical concentration and critical proportion, combined with quanti-
tative measures of drug resistance, automated detection and
continuous monitoring, exploring drug susceptibility in the dimen-
sions of concentration, proportion and time. Work still needs to be
done to resolve some discrepancies between phenotypic and
genotypic tests as in the case of ethambutol. In addition, group
4 and 5 antituberculous drugs8 and new ones, such as bedaquiline
and delamanid, will need to be tested.50,51 Hopefully, a more thor-
ough description of resistance in clinical strains will allow better
exploitation of available antituberculous agents in the treatment
Table 3. Genotype–phenotype relationship of the most prevalent resistance gene mutations
Drug Mutationa Low-level resistanceb Intermediate-level resistancec High-level resistanced
Isoniazid katG S315T (n¼99) 1/99 92/99 6/99
inhA promoter (n¼6) 5/6 1/6 0/6
Rifampicin rpoB S531L (n¼98) 1/98 2/98 95/98
rpoB D516V (n¼12) 2/12 9/12 1/12
rpoB H526L (n¼3) 2/3 0/3 1/3
rpoB H526Y (n¼4) 0/4 1/4 3/4
rpoB H526D (n¼6) 0/6 0/6 6/6
Rifabutin rpoB S531L (n¼87) 0/87 17/87 70/87
rpoB D516V (n¼9) 6/9 2/9 1/9
rpoB H526L (n¼2) 1/2 0/2 1/2
rpoB H526Y (n¼3) 0/3 0/3 3/3
rpoB H526D (n¼5) 0/5 0/5 5/5
Ethambutol embB M306I (n¼14) 13/14 1/14 0/14
embB M306V (n¼24) 14/24 10/24 0/24
Ethionamide inhA promoter (n¼8) 2/8 2/8 4/8
ethA (n¼21) 4/21 3/21 14/21
Streptomycin rrs a523c (n¼7) 0/7 2/7 5/7
rrs c526t (n¼8) 3/8 4/8 1/8
rpsL K43R (n¼55) 0/55 2/55 53/55
rpsL K88R (n¼9) 0/9 5/9 4/9
gidBe (n¼16) 9/16 7/16 0/16
Amikacin rrs a1408 mutation (n¼18) 0/18 0/18 18/18
rrs a1408 WT (n¼4) 4/4 0/4 0/4
Capreomycin rrs a1408 mutation (n¼18) 3/18 15/18 0/18
tlyAf (n¼5) 1/5 4/5 0/5
Ofloxacin gyrA A90V (n¼3) 0/3 3/3 0/3
gyrA S91P (n¼5) 0/5 5/5 0/5
gyrA D94G (n¼7) 0/7 6/7 1/7
Moxifloxacin gyrA A90V (n¼3) 2/3 1/3 0/3
gyrA S91P (n¼5) 0/5 4/5 1/5
gyrA D94G (n¼7) 0/7 7/7 0/7
aOnly single mutations were considered and mutations observed in less than three strains are not shown.
bLow-level resistance was defined as resistance at the screening concentration, but susceptibility at the intermediate drug concentration.
cIntermediate-level resistance was defined as resistance at the screening concentration and the intermediate concentration, but susceptibility at the
highest concentration.
dHigh-level resistance was defined as resistance at all concentrations tested.
eEighteen out 23 streptomycin-resistant strains with no mutation in rrs and rpsL were tested for gidB.
fThe six capreomycin-resistant strains WT for rrs 1400 were tested for tlyA.
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of drug-resistant TB disease, by tailoring therapy according to the
resistance characteristics of individual strains. The time has come
for personalized medicine in the treatment of drug-resistant TB
disease.
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